

REMARKS

Amendment to the Specification

Applicants have amended the specification herein to include a proper priority claim as the first, full paragraph following the title, pursuant to the requirements of 35 U.S.C. § 119(b) and 37 C.F.R. § 1.78(a)(2).

Status of claims

Original claims 1 to 15 have been canceled and new claims 16 to 26 have been added herein.

Support for the newly added claims can be found at least in original claims 1 to 15 and in the originally-filed specification. Specifically, support for new claims 16 to 21 can be found in original claims 1 to 3 and in the originally-filed specification at page 1, line 22 to page 2, line 18. Support for new claim 22 can be found in original claim 4 and in the originally-filed specification at least at page 19, lines 35 to 38. Support for new claim 23 can be found in original claim 5 and in the originally-filed specification at least at page 20, line 16 to page 21, line 25. Support for new claim 24 can be found in original claim 12 and in the originally-filed specification at least at page 13, lines 33 to 37. Finally, support for new claims 25 and 26 can be found in original claim 13 and in the originally-filed specification at least at page 7, line 11 to page 13, line 7. As such, no new matter has been added in the present amendments.

Applicants respectfully submit that the present amendments place the application in a form for immediate allowance.

If any fees other than those submitted herewith are due in connection with this response, including the fee for any required extension of time, for which Applicants hereby petition, please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: October 5, 2006

/Jeffrey H. Tidwell/

Jeffrey H. Tidwell
Attorney for Applicants
Registration No. 47,995

Pfizer Inc.
Patent Department
10555 Science Center Drive
San Diego, California 92121
Phone: (858) 638-3877
Fax: (858) 678-8233